Major study finds abatacept safe for rheumatoid arthritis patients over 10 years

A decade-long international study tracking cancer outcomes in rheumatoid arthritis patients on abatacept and competing drugs provides reassurance about the safety profile of this widely used immune-suppressing therapy. The findings matter for pharmaceutical companies, insurers, and health systems evaluating long-term treatment risks and benefits.

Originaltitel: Malignancy outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: Results from a 10-year international post-marketing study